Compare SGRP & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGRP | ENLV |
|---|---|---|
| Founded | 1967 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 26.6M |
| IPO Year | 1996 | 1995 |
| Metric | SGRP | ENLV |
|---|---|---|
| Price | $0.89 | $1.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 61.0K | ★ 11.2M |
| Earning Date | 11-14-2025 | 11-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $147,130,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.79 | N/A |
| 52 Week Low | $0.85 | $0.83 |
| 52 Week High | $2.28 | $2.10 |
| Indicator | SGRP | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 35.44 | 58.56 |
| Support Level | $0.87 | $0.89 |
| Resistance Level | $0.92 | $1.06 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 16.35 | 26.43 |
SPAR Group Inc is a merchandising and brand marketing services company, providing a broad range of sales-enhancing services to retailers across classes of trade and consumer goods manufacturers and distributors. It also provides a range of services to retailers, consumer goods manufacturers and distributors around the globe. The company divides its operations into three reportable regional segments: Americas, which is comprised of United States, Canada, Brazil and Mexico; Asia-Pacific (APAC), which is comprised of Japan, China, and India; and Europe, Middle East and Africa (EMEA), which is comprised of South Africa. It generates maximum revenue from the Americas.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.